|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cushing L, Jiang Z, Kuang P and Lü J: The
roles of microRNAs and protein components of the microRNA pathway
in lung development and diseases. Am J Respir Cell Mol Biol.
52:397–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ebrahimi A and Sadroddiny E: MicroRNAs in
lung diseases: Recent findings and their pathophysiological
implications. Pulm Pharmacol Ther. 34:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Islam KM Monirul, Shostrom V, Kessinger A
and Ganti AK: Outcomes following surgical treatment compared to
radiation for stage I NSCLC: A SEER database analysis. Lung Cancer.
82:90–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang
Y, Zhao H, Wu J, Zhang Y, Zhao L, et al: National survey of the
medical treatment status for non-small cell lung cancer (NSCLC) in
China. Lung Cancer. 77:371–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laskin JJ and Sandler AB: State of the art
in therapy for non-small cell lung cancer. Cancer Invest.
23:427–442. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Q, Xiao B, Ma X, Qu M, Li Y,
Nagarkatti P, Nagarkatti M and Zhou J: MicroRNAs associated with
the pathogenesis of multiple sclerosis. J Neuroimmunol 295–296.
148–161. 2016. View Article : Google Scholar
|
|
12
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meltzer PS: Cancer genomics: Small RNAs
with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bao L, Wang L, Wei G, Wang Y, Wuyun G and
Bo A: Role of microRNA-4458 in patients with non-small-cell lung
cancer. Oncol Lett. 12:3958–3966. 2016.PubMed/NCBI
|
|
15
|
Hu W, Jin P, Ding C and Liu W: miR-19a/b
modulates lung cancer cells metastasis through suppression of MXD1
expression. Oncol Lett. 12:1901–1905. 2016.PubMed/NCBI
|
|
16
|
Sahay D, Leblanc R, Grunewald TG,
Ambatipudi S, Ribeiro J, Clézardin P and Peyruchaud O: The
LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal
breast cancer. Oncotarget. 6:20604–20620. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maugeri-Saccà M, Coppola V, Bonci D and De
Maria R: MicroRNAs and prostate cancer: From preclinical research
to translational oncology. Cancer J. 18:253–261. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Liu YH, Diao HY, Ma J and Yao YL:
MiR-661 inhibits glioma cell proliferation, migration and invasion
by targeting hTERT. Biochem Biophys Res Commun. 468:870–876. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu T, Yuan J, Wang Y, Gong C, Xie Y and
Li H: MiR-661 contributed to cell proliferation of human ovarian
cancer cells by repressing INPP5J expression. Biomed Pharmacother.
75:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reddy SD, Pakala SB, Ohshiro K, Rayala SK
and Kumar R: MicroRNA-661, a c/EBPalpha target, inhibits metastatic
tumor antigen 1 and regulates its functions. Cancer Res.
69:5639–5642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH,
Li YH, Kim MK, Kim DM, Choi BS, Kim EG, et al: Runx3 inactivation
is a crucial early event in the development of lung adenocarcinoma.
Cancer Cell. 24:603–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee KS, Lee YS, Lee JM, Ito K, Cinghu S,
Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, et al: Runx3 is required
for the differentiation of lung epithelial cells and suppression of
lung cancer. Oncogene. 29:3349–3361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiao CZ, Wei W, Guo ZX, Zhang MY, Zhang
YF, Wang JH, Shi M, Wang HY and Guo RP: MicroRNA-34c-3p promotes
cell proliferation and invasion in hepatocellular carcinoma by
regulation of NCKAP1 expression. J Cancer Res Clin Oncol.
143:263–273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang H, Ju H, Zhang L, Lu H and Jie K:
microRNA-577 suppresses tumor growth and enhances chemosensitivity
in colorectal cancer. J Biochem Mol Toxicol. Feb 2–2017.(Epub ahead
of print). View Article : Google Scholar
|
|
28
|
Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G
and Wang Z: miR-143 inhibits bladder cancer cell proliferation and
enhances their sensitivity to gemcitabine by repressing IGF-1R
signaling. Oncol Lett. 13:435–440. 2017.PubMed/NCBI
|
|
29
|
Gandellini P, Giovannetti E and Nicassio
F: MicroRNAs in cancer management: Big challenges for small
molecules. Biomed Res Int. 2015:9821562015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mlcochova J, Faltejskova-Vychytilova P,
Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss
I, Vyzula R, et al: MicroRNA expression profiling identifies
miR-31-5p/3p as associated with time to progression in wild-type
RAS metastatic colorectal cancer treated with cetuximab.
Oncotarget. 6:38695–38704. 2015.PubMed/NCBI
|
|
31
|
Parpart S, Roessler S, Dong F, Rao V,
Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY and Wang XW:
Modulation of miR-29 expression by α-fetoprotein is linked to the
hepatocellular carcinoma epigenome. Hepatology. 60:872–883. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ
and Zheng JN: RUNX3 expression is lost in glioma and its
restoration causes drastic suppression of tumor invasion and
migration. J Cancer Res Clin Oncol. 137:1823–1830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dodurga Y, Avci CB, Satiroglu-Tufan NL,
Tataroglu C, Kesen Z, Doğan ZO, Yilmaz S and Gündüz C: Detection of
deleted in malignant brain tumors 1 and runt-related transcription
factor 3 gene expressions in bladder carcinoma. Mol Biol Rep.
39:4691–4695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sugiura H, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Mori Y, Ogawa R, Katada T, Harata K and Fujii Y:
Decreased expression of RUNX3 is correlated with tumor progression
and poor prognosis in patients with esophageal squamous cell
carcinoma. Oncol Rep. 19:713–719. 2008.PubMed/NCBI
|
|
35
|
Jiang Y, Tong D, Lou G, Zhang Y and Geng
J: Expression of RUNX3 gene, methylation status and
clinicopathological significance in breast cancer and breast cancer
cell lines. Pathobiology. 75:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC,
Lu PJ and Hsiao M: Loss of RUNX3 expression correlates with
differentiation, nodal metastasis, and poor prognosis of gastric
cancer. Ann Surg Oncol. 16:1686–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jili S, Eryong L, Lijuan L and Chao Z:
RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under
the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem Funct.
34:597–605. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen F, Liu X, Cheng Q, Zhu S, Bai J and
Zheng J: RUNX3 regulates renal cell carcinoma metastasis via
targeting miR-6780a-5p/E-cadherin/EMT signaling axis. Oncotarget.
Nov 8–2016.(Epub ahead of print).
|
|
39
|
Kim BR, Kang MH, Kim JL, Na YJ, Park SH,
Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the
metastasis and angiogenesis of colorectal cancer. Oncol Rep.
36:2601–2608. 2016.PubMed/NCBI
|
|
40
|
Yu GP, Ji Y, Chen GQ, Huang B, Shen K, Wu
S and Shen ZY: Application of RUNX3 gene promoter methylation in
the diagnosis of non-small cell lung cancer. Oncol Lett. 3:159–162.
2012.PubMed/NCBI
|
|
41
|
Torshabi M, Faramarzi MA, Yazdi M
Tabatabaei, Ostad SN and Gharemani MH: Runx3 expression inhibits
proliferation and distinctly alters mRNA expression of Bax in AGS
and A549 cancer cells. Iran J Pharm Res. 10:355–361.
2011.PubMed/NCBI
|
|
42
|
Lee JM, Shin JO, Cho KW, Hosoya A, Cho SW,
Lee YS, Ryoo HM, Bae SC and Jung HS: Runx3 is a crucial regulator
of alveolar differentiation and lung tumorigenesis in mice.
Differentiation. 81:261–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
